fda removes tirzepatide Lilly's weight-loss drug removed from FDA's shortage list fda removes tirzepatide from shortage

International Journal of Pharmacology, 29(6), 121-126

Qiao L, Hu J, Qiu X, Wang C, Peng J, Zhang C, et al

Have now completed one full year, gone back to DEA requesting additional quota

We also offer discounts on multi-month supplies such as 2- or 3-month packages to make ongoing therapy more affordable

Real-world clinical experience and post-trial observational data suggest many patients benefit from tirzepatide use extending beyond one year, though individual duration depends on personal health goals and response

Most patients notice improvements after 3 to 5 sessions, with maintenance sessions recommended for lasting effects